Table 2 HGSOC patient characteristics.

From: Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors

 

All patients

Low curvature

High curvature

 

Characteristic

(n = 45)

(n = 12)

(n = 33)

p

Age at diagnosis (years)

   

0.062

 Mean ± SD

58.0 ± 9.3

62.3 ± 7.5

56.4 ± 9.4

 

 Range

27.0–75.0

49.0–75.0

27.0–75.0

 

 Median (IQR)

58.0 (52.0–64.0)

64.0 (58.8–65.5)

55.0 (51.0–61.0)

 

Age at start of ICI (years)

   

0.023

 Mean ± SD

62.1 ± 8.7

67.1 ± 6.9

60.3 ± 8.7

 

 Range

37.0–78.0

55.0–78.0

37.0–77.0

 

 Median (IQR)

62.0 (56.0–69.0)

67.0 (63.3–70.3)

59.0 (55.0–66.0)

 

Stage at diagnosis

   

0.502

 III

25

8

17

 

 IV

20

4

16

 

Time from diagnosis to start of ICI (months)

   

0.581

Mean ± SD

50.9 ± 35.9

58.8 ± 43.1

48.1 ± 33.2

 

Range

5.3–166.0

17.4–166.0

5.3–123.1

 

Median (IQR)

49.4 (23.3–61.7)

44.5 (33.4–61.8)

49.4 (18.5–61.7)

 

Duration of ICI (weeks)

   

0.807

Mean ± SD

20.2 ± 23.6

14.3 ± 8.6

22.3 ± 27.0

 

Range

0.1–143.0

0.7–28.3

0.1–143.0

 

Median (IQR)

12.3 (7.7–23.1)

13.6 (7.8–20.3)

12.1 (7.7–23.1)

 

Overall survival (months)

   

0.007

 Mean ± SD

16.7 ± 11.7

8.8 ± 7.2

19.6 ± 11.7

 

 Range

0.4–44.8

0.4–27.4

0.4–44.8

 

 Median (IQR)

15.3 (6.5–24.6)

7.4 (4.9–10.9)

20.3 (11.1–26.0)

 

Sample type

   

0.010

 Metastasis

32.0

12

20

 

 Primary

13.0

0

13

 

Status at last follow-up

   

0.134

 Alive

13

1

12

 

 Dead

32

11

21

 

TMB

   

0.959

 Mean ± SD

3.7 ± 2.3

3.5 ± 1.9

3.8 ± 2.5

 

 Range

1.0–9.7

1.1–6.7

1.0–9.7

 

 Median (IQR)

3.3 (2.0–4.4)

2.6 (2.0–5.3)

3.3 (2.0–4.4)

 

FGA

   

0.005

 Mean ± SD

0.4 ± 0.2

0.3 ± 0.2

0.5 ± 0.2

 

 Range

0.005–0.871

0.005–0.629

0.092–0.871

 

 Median (IQR)

0.4 (0.3–0.6)

0.2 (0.1–0.4)

0.5 (0.4–0.6)

 

LST

   

0.024

 Mean ± SD

25.0 ± 10.3

19.3 ± 9.1

27.1 ± 10.0

 

 Range

2.0–51.0

2.0–32.0

2.0–51.0

 

 Median (IQR)

25.0 (20.0–29.0)

22.0 (13.5–25.8)

27.0 (22.0–34.0)

 

Platinum status at ICI

   

1.000

 Platinum Sensitive

6

1

5

 

 Platinum Resistant

39

11

28

 

BRCA1/2 Status

   

1.000

 Wild-type

35

9

26

 

 Mutation

10

3

7

 

ICI target

   

0.909

 PD-1/PD-L1

25

6

19

 

 PD-1/PD-L1 + CTLA-4

15

5

10

 

 PD-1/PD-L1 + other

4

1

3

 

 CTLA-4

1

0

1

 
  1. P values were obtained using two-sided Wilcoxon–Rank Sum test for continuous variables and Fisher-exact test for categorical variables.
  2. SD standard deviation, IQR interquartile range.
Back to article page